Blake A. Morrison, Pharm D.
Blake is dedicated expert in novel therapeutics development for multiple myeloma and has more than 30 years’ experience in the biopharmaceutical industry focused on the development of oncology therapeutics.
He is a co-founder of MYELOMA360. In addition, he worked at ONCOtracker helping bring the sBCMA Biomarker Test along in development and licensing. Blake has held multiple leadership roles in prominent biopharma companies and has been associated with multiple agents used in the treatment and management of multiple myeloma, including:
Additionally, he has development experience with several other approved products and investigational agents in multiple myeloma and other cancer malignancies.